TACTI-002 blew through trial expansion in short order. I am really going to enjoy watching all of you old timers celebrate hopefully soon. TACTI-mel showed durability in responders, and there’s pretty compelling reasons for TACTI-002 to do the same Bring on more patients, regardless of PDL1 status in an immunohistochemistry assay. If efti holds up all patients will be eligible for Keytruda. Throw away the test.
Ann: IMM presents positive interim phase 2 TACTI-002 data at SITC, page-23
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |